INTRODUCTION
Neuroblastoma (NB), the most common solid extracranial pediatric tumor, is heterogeneous in terms of its biological, genetic and morphological characteristics.
Such tumors exhibit diverse clinical behaviors whereby patients with similar clinicopathological features can have radically different outcomes. Since treatment strategies vary from surgery alone to intensive multimodal regimens, precise risk assessment is critical for therapeutic decisions. Currently, several clinical, biological and morphological parameters such as age at diagnosis, tumor stage, genomic amplification of MYCN oncogene, copy number alterations of the chromosomal regions 1p, 11q and 17q, ploidy and histological features, are regarded as markers of NB outcome [1] [2] [3] [4] . However, despite elaborate risk stratification strategies, there remain cases where these markers have demonstrated limited clinical utility.
Microarray gene expression studies have contributed to identify sets of genes of prognostic importance in numerous neoplasias, including NB [5] [6] [7] [8] [9] [10] [11] [12] [13] . Nevertheless, the use of microarrays in clinical practice is limited by the large sets of genes identified, the need for complex statistical analyses required to extract informative patterns from raw microarray data. Furthermore, there has been little overlap in the prognostic gene sets identified by different groups. To translate these profiles into clinically applicable tests, it is essential to reduce the number of genes and create profiles that can be analyzed with a conventional assay such as qRT-PCR.
In our previous study, we identified differentially expressed genes capable of discriminating between subgroups of NB with radically different clinical course; namely near-triploid (favorable prognosis) and near-diploid/tetraploid tumors (unfavorable prognosis). A substantial portion of these genes mapped to chromosomes 1 and 17, chromosomal regions found to be recurrently altered in NB 14 . Tumor cell ploidy has recently been included in the International Neuroblastoma Risk Group (INRG) classification system as a significant NB biomarker together with MYCN status and 11q23 allelic status 3 . Gene expression profiles associated with different NB ploidy
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Author Manuscript Published OnlineFirst on February 10, 2012; DOI: 10.1158/1078-0432.CCR- status may contribute to the identification of genes that are predictive of outcome. In this study, we investigated whether the identified gene expression profiling data allowed for the development of an outcome predictor model that could both accurately predict NB outcome, as well as be technically simple and applicable for routine clinical use. To this end, we examined the prognostic significance of 11 high-ranked, differentially expressed genes located on the chromosomes 1 and 17, chosen on the basis of our previous study 14 . The results of a qRT-PCR based analysis enabled the development of a single score predictor model based on the expression pattern of three genes, CHD5, PAFAH1B1 and NME1, strongly associated with patient outcome.
METHODS

Patients and samples
Tumor specimens from 96 NB patients were obtained at diagnosis from different (Table 1 and Supplementary Table 1 ).
The first 36 unselected cases of the training cohort (36 of 96 NB) were used to develop the gene-expression based model; the remaining 60 primary NB tumors were used as preliminary testing cohort. The complete training cohort (n=96) was subsequently used to refine the obtained model (Table 1 and Supplementary Table 1) .
A separate set of 120 primary NB tumors (hereafter referred as Set 1) of patients diagnosed and treated at the University Children's Hospital of Cologne, Department of Pediatric Oncology, Germany, was used as an independent, blinded set of RNA samples to validate the model by qRT-PCR.
Tumors were assessed by a pathologist, only tumors with >70% viable tumor cell content were included in the study. Risk assessment was defined by the INSS staging classification 1 intensive chemotherapy (including high-dose therapy and autologous stem-cell rescue), radiotherapy and surgery. Written informed consent was obtained from each subject or from his or her guardian before collection of samples. This study was approved by the Institutional Review Boards.
Gene expression data
Two published gene expression data sets from different platforms comprising 352 patients in total were used as validations sets. Expression data was downloaded from the National Centre of Biotechnology Information Gene Expression Omnibus (GSE3960   15   ) and from the European Bioinformatics Institute ArrayExpress database (E-TABM-38 9 ).
Updated clinical data was obtained from the authors. The validation sets will be hereafter referred to as Set 2 (n=101 15 ) and Set 3 (n=251 9 ). Set 2 and Set 3 were used to assess the prediction performance of the model across different NB expression data sets. Set 3 includes expression data of 110 patients comprised in Set 1. This set of overlapping samples (n=110) was used to estimate the prediction performance of the model in NB tumors analyzed by different expression methods (qRT-PCR and microarray analyses). Set 3 was used for further analyses aimed to test the classification performance of the model as compared with current risk stratification systems. Set 3 was selected for these analyses since it comprises a full representation of the NB tumor spectra and a median follow-up time >5-years (Table 1 and   Supplementary Table 5 ).
The analyses were performed blinded of clinical and biological data, and sample identification.
RNA isolation and quantitative real-time PCR
Total RNA was isolated from the 96 snap frozen samples using Tri Reagent (Sigma, US), following manufacturers' protocols. cDNA was synthesized from 1µg total RNA as previously described 14 . Gene expression was quantified with TaqMan Gene Expression Assays (Supplementary Appendix 
Statistical analysis
Gene expression values were normalized with a z-score transformation. From the 96 NB cases of the training set, the first 36 unselected cases were employed for the selection of genes strongly associated, as independent factors, with OS and EFS using Cox regression models. Relapse, progression and death from disease were considered as events. Genes significantly associated with OS and EFS were further tested using Principal Components Analysis (PCA) (multivariable unsupervised method) with the VARIMAX rotation method and tested using Cox regression models.
This procedure was performed by means of a stepwise backward selection approach.
Briefly, at each step of the backward selection procedure, one gene was removed from the set of genes. To select which gene was discarded (not independent predictor or the least statistically significant), all the possible combinations of genes were tested by removing and then reintroducing one by one each gene following an iterative procedure. Each gene set combination was thus analyzed using PCA and tested with and EFS. This backward selection procedure concluded when the combination with the minimum set of genes statistically significantly associated with OS and EFS is found.
After testing all the combinations, genes that were not independent predictors and the least statistically significant genes were discarded. The outcome predictor model was developed using a linear combination of the z-score transformed expression value of each of the selected genes, weighted by the regression coefficients (α) of components with Eigenvalue >1. The model was tested using the remaining 60 NB cases of the training set. The entire training cohort (n=96) was used to refine the model. To validate the final model we applied it to different expression data sets obtained by qRT-PCR (Set 1) and microarray gene expression studies (Set 2 and Set 3). The performance of the model was examined with multivariable Cox regression models using a stepwise variable selection procedure. 
RESULTS
Selection of genes for the outcome predictor score model
In our previous study, we found specific transcriptional profiles associated with NB with different ploidy 14 . A statistically significant number of genes found to be differentially expressed mapped to chromosomes 1 (p=0.01) and 17 (p<0.0001), chromosomes with aberrations reported to be consistently associated with outcome in pathogenesis. The expression levels of the 11 genes were quantified using qRT-PCR in 36 NB tumors (Supplementary Table 1 ). To assess the association with OS and EFS, qRT-PCR expression levels were normalized by z-score transformation and analyzed using univariable Cox regression models (Supplementary Appendix Table 3 ).
High expression of six genes was found to be significantly associated (P-value<0.05) as independent factors with outcome: five (RERE, PTPRF, GNB1, CHD5 and PAFAH1B1) were associated with longer OS and EFS (Hazard ratio [HR] <1 for all) and one gene, NME1, was associated with worse clinical outcome (HR>1). These six genes were considered potential prognostic markers and were further studied. We Figure 1A and 1B).
The first approximation of the model was tested using an independent set of 60 primary NB tumors (Supplementary Table 1 Figure 1C and 1D).
In order to improve the performance of the predictor model, we proceeded to reestimate the component coefficient scores of the three genes using the entire training cohort of 96 cases (Supplementary Table 1 Figure 1G and 1H).
Validation of outcome predictor model using independent microarray data
Research. Table 2 . Furthermore, in a multivariable Cox regression analysis evaluating the prognostic parameters, the model remained significantly associated with OS and EFS (P<0.001 for all), showing thus to be independent of other prognostic markers (Table 3) .
To further assess the model across different data sets, the prediction Table 5 ). All classification systems separated patients into groups with significant differences in OS and EFS ( Figure 2 , Table 4 
DISCUSSION
In this study, we developed a PCR-based predictor model using the expression pattern of just three-genes strongly associated with outcome of patients with NB.
CHD5, PAFAH1B1 and NME1 were identified through the analysis of the prognostic significance of 11 genes found differentially expressed in our previous study 14 . The results of a qRT-PCR-based evaluation of the expression pattern of the selected genes in a training set of 96 primary NB tumors enabled the development of a single score predictor model. Its validity was assessed using different expression data sets obtained from qRT-PCR and microarray gene expression studies comprising a total of 362 patients 9, 15 . Our scoring method reliably stratified patients into NB groups with markedly divergent clinical course. Multivariable Cox models showed that the developed scoring model was an independent predictor marker for survival. Moreover, the prediction performance of the three-gene model was found to be as robust as the international NB risk stratification systems based on a combination of clinical and biological parameters.
Our classifier also significantly discriminated between patients in most subgroups defined by currently used prognostic markers. Interestingly, a significantly higher prediction performance than current risk stratification systems was observed in clinically relevant subgroups such as children with localized disease MYCN nonamplified. This is a relevant finding, since outcome prediction in this biologically broad 
The genes that comprise the model have been previously reported to be involved in NB biology. CHD5 is a tumor suppressor gene located on chromosome 1p36.31, region recurrently lost in high-risk NB [17] [18] [19] [20] [21] . Expression of this ATP-dependent chromatin remodeling helicase has been found to be restricted to neuronal-derived tissues and absent in NB cell lines and NB primary tumors with high risk features, undifferentiated neuroblasts, MYCN amplification, advanced stage and 1p monosomy 18, 21 . Association between CHD5 expression and favorable prognosis in NB has been reported previously in microarray gene expression studies 8, 11, 14, 22 . PAFAH1B1, located on chromosome 17p13.3, encodes an acetylhydrolase involved in cerebral cortex development, neuronal migration and axonal growth 23 . Mutations of PAFAH1B1 have been related to the MillerDieker lissencephaly syndrome 23, 24 . We identified PAFAH1B1 expression in low-risk NB tumors, while in high risk tumors expression is significantly diminished. PAFAH1B1 has been reported previously associated to favorable prognosis in NB 7 . In our study, high expression of both CHD5 and PAFAH1B1 correlated with prolonged survival. In contrast, NME1 displayed high expression levels in high-risk NB tumors, as reported previously 25, 26 . NME1, located on a region frequently gained in clinically aggressive NB 17q21.3 27, 28 , has been reported in several microarray analyses to be associated with high-risk NB 6, 12, 13 . The product of the NME1 gene is a nucleoside diphosphate kinase involved in cell proliferation, normal development and cell differentiation 29 .
Prognostic models, similar to ours, and gene-signatures based on small sets of genes, have been reported previously to predict clinical outcome in diffuse large-B-cell associated with patient outcome and created a prognostic model that can be applied in routine laboratories using conventional qRT-PCR assay. Our preliminary results provide evidence of a prognostic model that can accurately define NB clinical risk groups and could thus assist therapeutic decisions in NB patients.
In conclusion, we propose a robust and technically simple PCR-based one score predictor model that requires only minimal amount of mRNA, is easy to interpret, reproducible, and cost-effective for most laboratories. These features make the model a potentially practical classifier for NB risk stratification that could help refine current risk stratification systems. The potential of this prototype model remains to be fully validated using qRT-PCR in a large, prospective and independent cohort of NB patient samples.
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